JP2019532029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532029A5 JP2019532029A5 JP2019510396A JP2019510396A JP2019532029A5 JP 2019532029 A5 JP2019532029 A5 JP 2019532029A5 JP 2019510396 A JP2019510396 A JP 2019510396A JP 2019510396 A JP2019510396 A JP 2019510396A JP 2019532029 A5 JP2019532029 A5 JP 2019532029A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- compound
- disorder
- pharmaceutically acceptable
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 238000009825 accumulation Methods 0.000 claims description 7
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 3
- 208000006101 succinic semialdehyde dehydrogenase deficiency Diseases 0.000 claims 3
- 108700004974 succinic semialdehyde dehydrogenase deficiency Proteins 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010012559 Developmental delay Diseases 0.000 claims 1
- 206010021118 Hypotonia Diseases 0.000 claims 1
- 208000007379 Muscle Hypotonia Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000027765 speech disease Diseases 0.000 claims 1
- UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical compound OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 208000035475 disorder Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 229910052805 deuterium Inorganic materials 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 201000008937 atopic dermatitis Diseases 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010012434 Dermatitis allergic Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 208000006934 radiodermatitis Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010010996 Corneal degeneration Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 2
- 201000002287 Keratoconus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000004781 bullous keratopathy Diseases 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 206010023365 keratopathy Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000036558 skin tension Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000008986 Pyridoxine-dependent epilepsy Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- JIRJHEXNDQBKRZ-UHFFFAOYSA-N phosgene oxime Chemical compound ON=C(Cl)Cl JIRJHEXNDQBKRZ-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378065P | 2016-08-22 | 2016-08-22 | |
| US62/378,065 | 2016-08-22 | ||
| PCT/US2017/047945 WO2018039192A1 (en) | 2016-08-22 | 2017-08-22 | Aldehyde trapping compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532029A JP2019532029A (ja) | 2019-11-07 |
| JP2019532029A5 true JP2019532029A5 (enExample) | 2020-10-01 |
Family
ID=61190657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510396A Pending JP2019532029A (ja) | 2016-08-22 | 2017-08-22 | アルデヒド補足化合物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180050989A1 (enExample) |
| EP (1) | EP3500256A4 (enExample) |
| JP (1) | JP2019532029A (enExample) |
| CN (1) | CN109640983A (enExample) |
| AU (1) | AU2017317524A1 (enExample) |
| CA (1) | CA3032521A1 (enExample) |
| CO (1) | CO2019001625A2 (enExample) |
| MX (1) | MX2019001722A (enExample) |
| WO (1) | WO2018039192A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| KR20180116416A (ko) | 2016-02-28 | 2018-10-24 | 알데이라 테라퓨틱스, 아이엔씨. | 사이클로덱스트린으로의 알레르기성 안질환의 치료 |
| CN109152774A (zh) | 2016-05-09 | 2019-01-04 | 奥尔德拉医疗公司 | 眼部炎性病症和疾病的组合治疗 |
| WO2018170476A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CN111356451A (zh) * | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| US20200038392A1 (en) | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| CN113056353B (zh) | 2018-09-25 | 2022-11-01 | 奥尔德拉医疗公司 | 用于治疗干眼病的调配物 |
| WO2020123730A1 (en) * | 2018-12-12 | 2020-06-18 | Teva Pharmaceuticals International Gmbh | Solid state forms of reproxalap |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN113784954A (zh) * | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| JP2023507900A (ja) * | 2019-12-30 | 2023-02-28 | 中国医▲薬▼研究▲開▼▲発▼中心有限公司 | 三環式化合物、及びその調製方法、及びその医薬的使用 |
| CA3174416A1 (en) * | 2020-04-13 | 2021-10-21 | Todd Brady | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
| WO2021231792A1 (en) * | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2021248031A1 (en) * | 2020-06-04 | 2021-12-09 | Aldeyra Therapeutics, Inc. | Dry eye disease biomarkers and their use for treatment |
| JP2024503325A (ja) * | 2020-12-29 | 2024-01-25 | 中国医▲薬▼研究▲開▼▲発▼中心有限公司 | 三環式化合物、及びその調製方法、及びその医薬的使用 |
| WO2022267930A1 (zh) * | 2021-06-25 | 2022-12-29 | 中国医药研究开发中心有限公司 | 三环化合物及其制备方法和医药用途 |
| WO2023192372A1 (en) * | 2022-03-29 | 2023-10-05 | Aldeyra Therapeutics, Inc. | Methods of treating sjögren-larssen syndrome |
| CN122458974A (zh) * | 2023-12-28 | 2026-07-24 | 珠海联邦制药股份有限公司 | Rasp抑制剂在制备治疗或预防慢性咳嗽、哮喘及酒精性肝病疾病的药物中的应用 |
| CN120607478A (zh) * | 2024-03-06 | 2025-09-09 | 深圳湾实验室 | 预防和治疗醛代谢紊乱引起的相关疾病的化合物及其用途 |
| CN121652111A (zh) * | 2024-09-11 | 2026-03-13 | 深圳新锐基因科技有限公司 | 一种基于ai设计的活性醛类物质抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) * | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| KR20150118106A (ko) * | 2012-12-20 | 2015-10-21 | 알데이라 테라퓨틱스, 아이엔씨. | 페리-카르비놀 |
| CN111135171B (zh) * | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| KR101646666B1 (ko) * | 2015-03-26 | 2016-08-08 | 엘지이노텍 주식회사 | 발광 소자, 이 소자를 포함하는 발광 소자 패키지, 및 이 패키지를 포함하는 조명 장치 |
| KR20180073553A (ko) * | 2015-08-21 | 2018-07-02 | 알데이라 테라퓨틱스, 아이엔씨. | 알데히드 접합체 및 이의 용도 |
| CN118724806A (zh) * | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
-
2017
- 2017-08-22 EP EP17844261.2A patent/EP3500256A4/en not_active Withdrawn
- 2017-08-22 MX MX2019001722A patent/MX2019001722A/es unknown
- 2017-08-22 CN CN201780051309.5A patent/CN109640983A/zh active Pending
- 2017-08-22 WO PCT/US2017/047945 patent/WO2018039192A1/en not_active Ceased
- 2017-08-22 CA CA3032521A patent/CA3032521A1/en not_active Abandoned
- 2017-08-22 AU AU2017317524A patent/AU2017317524A1/en not_active Abandoned
- 2017-08-22 JP JP2019510396A patent/JP2019532029A/ja active Pending
- 2017-08-22 US US15/682,955 patent/US20180050989A1/en not_active Abandoned
-
2019
- 2019-02-22 CO CONC2019/0001625A patent/CO2019001625A2/es unknown
- 2019-04-04 US US16/374,845 patent/US20200062712A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523700A5 (enExample) | ||
| TW202237087A (zh) | 作為醫藥活性化合物之大麻素衍生物及其製備方法 | |
| JP2021105002A5 (enExample) | ||
| JP2016506391A5 (enExample) | ||
| RU2018145691A (ru) | Заболевания, связанные с токсичным альдегидом, и их лечение | |
| JP2025065545A (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| JP2018104454A5 (enExample) | ||
| JP2016199576A5 (enExample) | ||
| FR2889525A1 (fr) | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. | |
| US10632067B2 (en) | Use of selected anticholinergic zwitterions | |
| CA3137301A1 (en) | Polymorphic compounds and uses thereof | |
| RS63566B1 (sr) | Antifungalna jedinjenja i procesi izrade | |
| AU2017341769B2 (en) | N-Acylethanolamide derivatives and uses thereof | |
| JP2018537513A5 (enExample) | ||
| JP2017534665A5 (enExample) | ||
| JP2017534664A5 (enExample) | ||
| JP2022545047A (ja) | ３－ヒドロキシ－５－プレグナン－２０－オン誘導体およびその使用 | |
| JP2015535850A5 (enExample) | ||
| EP4296670B1 (en) | Sulfopropanoic acid derivatives for treating neurodegenerative disorders | |
| US20170260138A1 (en) | Process for producing diamine derivative | |
| JP7572007B2 (ja) | ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途 | |
| JP2010522182A5 (enExample) | ||
| JP2010522181A5 (enExample) | ||
| JPH08508044A (ja) | 新規シクロプロピル誘導体類、その調製法および応用 | |
| KR102208220B1 (ko) | 신규한 세리놀계 화합물, 이를 포함하는 화장료 조성물 및 약학 조성물 |